Zymergen Overview
- Year Founded
-
2013
- Status
-
Out of Business
- Employees
-
1,000
- Latest Deal Type
-
Bankr. Admin/Reorg
Zymergen General Information
Description
Developer of microbe-based diversified inputs and technology intended for agricultural and industrial applications. The company specializes in designing, developing, and manufacturing bio-based breakthrough products that deliver value to customers in a broad range of industries with a combination of biology, chemistry, software, and automation, helping companies to design and create new materials.
Contact Information
Website
www.zymergen.comCorporate Office
- 5959 Horton Street
- Floor 7
- Emeryville, CA 94608
- United States
Corporate Office
- 5959 Horton Street
- Floor 7
- Emeryville, CA 94608
- United States
Zymergen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Bankruptcy: Admin/Reorg | 03-Oct-2023 | Completed | Bankruptcy: Admin/Reorg | |||
| 12. Merger/Acquisition | 19-Oct-2022 | Completed | Generating Revenue | |||
| 11. IPO | 22-Apr-2021 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series D) | 29-Jul-2020 | Completed | Generating Revenue | |||
| 9. Debt - General | 01-Jan-2019 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 13-Dec-2018 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Private | 29-Nov-2017 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series B) | 29-Nov-2017 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B) | 07-Oct-2016 | $130M | $174M | Completed | Generating Revenue | |
| 4. Early Stage VC (Series A) | 04-Jun-2015 | $36.6M | $43.6M | Completed | Generating Revenue |
Zymergen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 26,158,833 | $0.001000 | $0.02 | $0.25 | $0.25 | 1x | $0.25 | 9.5% |
| Series A | 21,998,250 | $0.001000 | $0.13 | $1.66 | $1.66 | 1x | $1.66 | 7.99% |
Zymergen Comparisons
Industry
Financing
Details
Zymergen Competitors (8)
One of Zymergen’s 8 competitors is Arzeda, a Venture Capital-Backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arzeda | Venture Capital-Backed | Seattle, WA | ||||
| Amyris (Biotechnology) | Private Equity-Backed | Emeryville, CA | ||||
| BioTork | Venture Capital-Backed | Gainesville, FL | ||||
| Ingenza | Venture Capital-Backed | Penicuik, United Kingdom | ||||
| Twist Bioscience | Formerly VC-backed | South San Francisco, CA |
Zymergen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zymergen Patents
Zymergen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024059180-A1 | Soil-based phenotypic screening assays | Inactive | 15-Sep-2022 | ||
| WO-2024049682-A2 | Proteins for cross-linking biopolymers | Inactive | 01-Sep-2022 | ||
| WO-2024049682-A3 | Proteins for cross-linking biopolymers | Inactive | 01-Sep-2022 | ||
| WO-2024049682-A9 | Proteins for cross-linking biopolymers | Inactive | 01-Sep-2022 | ||
| WO-2024044505-A1 | Adhesive composition | Inactive | 22-Aug-2022 | C09J163/00 |
Zymergen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zymergen Acquisitions (3)
Zymergen’s most recent deal was a Merger/Acquisition with Lodo Therapeutics for . The deal was made on 16-May-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Lodo Therapeutics | 16-May-2021 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| enEvolv | 19-Mar-2020 | Merger/Acquisition | Biotechnology | ||
| Radiant Genomics | 08-Jan-2018 | Merger/Acquisition | Other Commercial Services |
Zymergen ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.03 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Zymergen Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| 1776 Pharmaceuticals | Emeryville, CA | 2020 |
Zymergen FAQs
-
When was Zymergen founded?
Zymergen was founded in 2013.
-
Where is Zymergen headquartered?
Zymergen is headquartered in Emeryville, CA.
-
What is the size of Zymergen?
Zymergen has 1,000 total employees.
-
What industry is Zymergen in?
Zymergen’s primary industry is Biotechnology.
-
Is Zymergen a private or public company?
Zymergen is a Private company.
-
What is Zymergen’s current revenue?
The current revenue for Zymergen is .
-
How much funding has Zymergen raised over time?
Zymergen has raised $1.57B.
-
Who are Zymergen’s competitors?
Arzeda, Amyris (Biotechnology), BioTork, Ingenza, and Twist Bioscience are some of the 8 competitors of Zymergen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
